Breastfeeding and vitamin D supplementation reduce the risk of Kawasaki disease in a German population-based case-control study

Table 2 Clinical details of KD vs. control cases

	KD cases	Control cases
	(n = 308)	(n = 326)
Age in years^a
Median	6.5	6.3
Sex, n (%)
Female	114 (37)	137 (42)
Male	194 (63)	189 (58)
KD diagnosis, n (%)
Complete	269	n.a.
Incomplete with laboratory changes ^b	15	n.a.
Incomplete with CAA	24	n.a.
Days until start of IVIG therapy
Average	6.6	n.a.
Min – max	0–32	n.a.
Refractory to IVIG treatment ^c
Yes > 1 IVIG cycle	29 (13.4%)	n.a.
Therapy with steroids, n (%)
Yes, for KD treatment	53 (17.2)	n.a.
Yes, for other reasons	9 (2.9)	n.a.
CAA in acute phase, n (%)
Yes	36 (11.6)	n.a.
CAA after one year ^c, n (%)
Yes	13 (5.9)	n.a.

^aat the end of the case-control study survey (i.e, March 22, 2017)
^b according to the guidelines of the American Heart Association at least three other abnormal supplemental laboratory findings, namely (1) increased alanine transaminase, (2) albumin ≤3.0 g/dL, (3) leukocyturia, (4) anaemia for age, (5) leukocytosis (≥15,000/mm³) (6) thrombocytosis (≥450,000/mm³) [16]
^cfor cases reported in 2013/2014 n = 217; CAA = coronary artery aneurysma; n.a. = not applicable

ISSN: 1471-2431